Literature DB >> 31020134

Melioidosis: an unusual cause of infective endocarditis: a case report.

Tonnii Sia1, Yuwana Podin2, Teik-Beng Chuah3, Jin-Shyan Wong4,5.   

Abstract

INTRODUCTION: As a causal organism in infective endocarditis, Burkholderia pseudomallei is rare. Burkholderia pseudomallei is intrinsically resistant to aminoglycosides but a gentamicin-susceptible strain was discovered in Sarawak, Malaysian Borneo in 2010. We report the first occurrence of infective endocarditis due to the gentamicin-susceptible strain of B. pseudomallei. CASE
PRESENTATION: A 29-year-old man presented with pneumonia and melioidosis septicaemia. His condition was complicated with infective endocarditis and septic emboli to the brain. Despite difficulties in reaching a diagnosis, the patient was successfully treated using intravenous gentamicin and ceftazidime and was discharged well. DISCUSSION: The role of gentamicin in the treatment of the gentamicin-susceptible strain of B. pseudomallei remains unclear.

Entities:  

Keywords:  Bintulu; Borneo; Burkholderia pseudomallei; Case report; Gentamicin; Gentamicin susceptible strain; Infective endocarditis; Malaysia; Melioidosis; Sarawak

Year:  2018        PMID: 31020134      PMCID: PMC6177064          DOI: 10.1093/ehjcr/yty055

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Burkholderia pseudomallei is an unusual cause of infective endocarditis. Burkholderia pseudomallei is known to be resistant to many antibiotics, including aminoglycosides. A strain of B. pseudomallei that is gentamicin-susceptible was found in Sarawak in Malaysian Borneo in 2010. The standard intensive phase therapy using carbapenem or ceftazidime can be instituted together with intravenous gentamicin for its synergistic effect in the treatment of infective endocarditis caused by the gentamicin susceptible strain of B. pseudomallei.

Introduction

Melioidosis is caused by the bacterium Burkholderia pseudomallei. It is endemic in many regions in Southeast Asia and Northern Australia. It is also increasingly reported in other tropical countries. It has a high mortality rate due to its systemic involvement and intrinsic resistance to a myriad of antibiotics. A novel strain of gentamicin-susceptible B. pseudomallei was recently reported to be predominantly found in the central region of Sarawak in Malaysian Borneo. Infective endocarditis causes significant morbidity and mortality., Complications of infective endocarditis include thromboembolic events, which could be life-threatening. Treatment of infective endocarditis requires the administration of an effective intravenous (IV) antibiotic over a prolonged duration. Common organisms identified for infective endocarditis are Streptococci and Staphylococci, both of which contributed to 80% of cases. We report the first occurrence of infective endocarditis due to the gentamicin-susceptible strain of B. pseudomallei in a tertiary hospital in central Sarawak of Malaysian Borneo.

Timeline

Case presentation

The patient, a regular and heavy consumer of alcohol, was a 29-year-old male lumberjack with no known medical illness. He had been having fever and cough for 2 weeks. He was brought to the hospital in a confused state after being reported missing from work for a few days. The patient presented with septic shock, which was consistent with the definition of Sepsis-3. He was in a very confused state and was talking irrelevantly. His Glasgow Coma Scale (GCS) registered E4V2M5. His temperature was 38.0°C, blood pressure was 85/42 mmHg, and his pulse rate was 135 b.p.m. He also had neck stiffness, bilateral upper and lower limbs power registered at least three, while his tone and reflexes were normal. He had normal heart sounds with no murmur and bilateral lung crepitations. The patient was given fluid resuscitation and required a vasopresssor for blood pressure support. He was also put on a mechanical ventilator before being admitted into the intensive care unit (ICU). Initial blood investigations showed anaemia and thrombocytopenia with normal total white cells and renal function. Ultrasonography examination showed the presence of splenic microabscesses and chest radiograph showed bilateral lung fields consolidation. Computed tomography (CT) of the brain was normal and lumbar puncture examination of the cerebrospinal fluid on admission showed no signs of inflammation or infection. The patient’s blood culture taken on admission grew B. pseudomallei. This was confirmed by a real-time polymerase chain reaction assay targeting the type III secretion system (TTS1). This B. pseudomallei isolate appeared to be gentamicin-susceptible by the Kirby–Bauer disk diffusion susceptibility test (Table ). He remained bacteraemic with positive blood cultures on Day 6 and 12 of admission yielding B. pseudomallei with the same antibiogram pattern. Subsequent blood cultures on Day 24, 26 and 27 of admission had no growth.
Table 1

Antibiogram of B. pseudomallei isolate based on disk diffusion test

Antibiotics testedDisk diffusion result
AmpicilinSensitive
CeftazidimeSensitive
CiprofloxacinSensitive
Trimethoprim-sulfamethoxazoleSensitive
ImipenemSensitive
MeropenemSensitive
TetracyclineSensitive
GentamicinSensitive
Antibiogram of B. pseudomallei isolate based on disk diffusion test The patient was administered IV noradrenaline upon admission. The highest dose used was 0.27 mcg/kg/min on Day 4 of admission, and he was subsequently weaned off after a week. Upon admission, he was empirically given IV ceftazidime and IV C-penicillin. On Day 4 of admission, antibiotics were escalated to IV imipenem in view of the patient’s persistent high-grade temperature and leukopenia. He required ventilatory support on a high setting for 2 weeks. During the second week of intensive phase therapy with IV antibiotics, he was started on oral trimethoprim-sulfamethoxazole (co-trimoxazole). His condition was complicated with ventilator-associated pneumonia. Culture of endotracheal secretions grew a multidrug resistant Acinetobacter baumanii, which was treated successfully with high dose IV ampicilin-sulbactamfor 14 days. He also developed sepsis-induced supraventricular tachycardia which resolved spontaneously. In the third week of admission, there was a new onset of left-sided hemiparesis (muscle power 1/5) and pansystolic murmur with thrills at the apex of the heart. A repeat CT of the brain showed a right corona radiata infarct with a high parietal petechia haemorrhage (Figure ). An echocardiogram showed a thickened mitral valve with an oscillating mass at the posterior mitral valve leaflet suggestive of vegetation (Figure ) with a moderate eccentric mitral regurgitation.
Figure 1

(A) Axial plain computed tomography brain shows there is a small hyperdense punctate haemorrhage at right high parietal region. (B) Axial plain computed tomography brain shows ill-defined hypodense area at right basal ganglia in keeping with infarction.

Figure 2

Echocardiogram of parasternal long-axis view showed an oscillating mass of 0.3 cm × 0.8 cm attached to posterior mitral leaflet suggestive of vegetation.

(A) Axial plain computed tomography brain shows there is a small hyperdense punctate haemorrhage at right high parietal region. (B) Axial plain computed tomography brain shows ill-defined hypodense area at right basal ganglia in keeping with infarction. Echocardiogram of parasternal long-axis view showed an oscillating mass of 0.3 cm × 0.8 cm attached to posterior mitral leaflet suggestive of vegetation. The intensive phase therapy for melioidosis was extended to 6 weeks using IV ceftazidime, and we added IV gentamicin at the dose of 60 mg, 8-hourly for 14 days. He was also given concurrent oral co-trimoxazole, which was subsequently continued as monotherapy in the eradication phase therapy for melioidosis. He was discharged after 12 weeks of admission with minimal residual left sided weakness (Modified Rankin Score of 2). The patient was able to perform all activities of daily living independently with intact cognitive function. He was subsequently transferred to a cardiac referral centre for definitive management. He remained well during follow-up in the cardiac centre at nine months from initial presentation. Echocardiogram showed that the vegetation on mitral valve had resolved with residual moderate mitral regurgitation and left ventricular ejection fraction of 66.5%. He remained in Modified Rankin Score of 2.

Discussion

Majority of the melioidosis cases are presented with bacteraemia and pneumonia is a common presentation. Cardiac involvement is very rare. A prospective study on melioidosis in Darwin reported pericarditis in only 4 out of 540 cases. As well, melioidosis pericardial effusion was reported in around 1–3% of the total cases in previous studies., A defective native heart valve, however, is a predisposition for infective endocarditis. And B. pseudomallei was recently found to cause infective endocarditis., This case illustrates that of a young man, with no known medical illness, who presented with disseminated melioidosis but, which was complicated with infective endocarditis and cerebral infarct. The diagnosis of infective endocarditis was unexpected because the patient was initially sedated and ventilated. Infective endocarditis was only discovered upon cessation of sedative medications, when he was found to have hemiparesis. A possible septic embolus was suspected. This led to the discovery of the prolapsed mitral valve, which had a vegetation. Infective endocarditis was complicated with septic emboli to the brain. This resulted in cerebral infarct and haemorrhages as seen in this case. Gentamicin is not used for treatment of melioidosis because B. pseudomallei is intrinsically resistant to penicillin, first and second-generation cephalosporin, aminoglycosides, and macrolides., However, this patient was infected by the gentamicin-susceptible B. pseudomallei strain. Therefore, we decided to use the combination of ceftazidime and gentamicin for the treatment of infective endocarditis in this patient. This was based on the experience of the synergistic effect of cephalosporins and aminoglycosides in the treatment of infective endocarditis. There are currently no guidelines on the treatment of melioidosis infective endocarditis. The identification of the specific aetiologic organism of infective endocarditis was important for the appropriate antibiotic therapy. In managing this case, we used 6 weeks of intensive phase antibiotics in the treatment of melioidosis, which was also consistent with the duration of treatment of infective endocarditis.

Conclusion

Melioidosis infective endocarditis is rare and reaching a diagnosis can be difficult. The intensive phase of melioidosis treatment must coincide with the duration of treatment of infective endocarditis. This would require clinical judgement, which would be guided by the patient’s clinical response and blood culture results. The use of gentamicin in the intensive phase of treatment for the gentamicin-susceptible B. pseudomallei strain requires further study.
WeekDayPatient’s progressCulture siteCulture result
11Septic shock secondary to pneumoniaBlood Burkholderia pseudomallei
Stared intravenous (IV) ceftazidime and IV C-penicillin
3–4Developed ventilator associated pneumonia
6Blood culture taken on first day confirmed for B. pseudomalleiBlood B. pseudomallei
28Weaned off inotropeRespiratory tractMultidrug-resistant Acinetobacter baumanii
11Respiratory tractMultidrug-resistant A. baumanii
12Blood B. pseudomallei
14Started on oral bactrim
24BloodNo growth
325Left side hemiplegia and pansystolic murmur
Echocardiography and computed tomography of the brain done
26BloodNo growth
27Weaned from ventilator supportBloodNo growth
5Started on IV gentamicin
7Completed intensive phase of antibiotics and physiotherapy. Patient was discharged from hospital
36Last follow-up visit
  9 in total

1.  Melioidosis pericarditis mimicking tuberculous pericarditis.

Authors:  Ploenchan Chetchotisakd; Siriluck Anunnatsiri; Songsak Kiatchoosakun; Churairat Kularbkaew
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

2.  Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei.

Authors:  Ryan T Novak; Mindy B Glass; Jay E Gee; Daniel Gal; Mark J Mayo; Bart J Currie; Patricia P Wilkins
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

3.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

4.  Endocarditis in melioidosis

Authors:  L B Piyasiri; S A Wickramasinghe; V C Lekamvasam; E M Corea; R Gunarathne; U Priyadarshana
Journal:  Ceylon Med J       Date:  2016-12-30

Review 5.  Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment.

Authors:  Bart J Currie
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

6.  The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study.

Authors:  Bart J Currie; Linda Ward; Allen C Cheng
Journal:  PLoS Negl Trop Dis       Date:  2010-11-30

7.  Burkholderia pseudomallei isolates from Sarawak, Malaysian Borneo, are predominantly susceptible to aminoglycosides and macrolides.

Authors:  Yuwana Podin; Derek S Sarovich; Erin P Price; Mirjam Kaestli; Mark Mayo; KingChing Hii; Hieung Ngian; SeeChang Wong; IngTien Wong; JinShyan Wong; Anand Mohan; MongHow Ooi; TemLom Fam; Jack Wong; Apichai Tuanyok; Paul Keim; Philip M Giffard; Bart J Currie
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

8.  Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis.

Authors:  Direk Limmathurotsakul; Nick Golding; David Ab Dance; Jane P Messina; David M Pigott; Catherine L Moyes; Dionne B Rolim; Eric Bertherat; Nicholas Pj Day; Sharon J Peacock; Simon I Hay
Journal:  Nat Microbiol       Date:  2016-01-01       Impact factor: 17.745

9.  A traveller presenting with severe melioidosis complicated by a pericardial effusion: a case report.

Authors:  Detlev Schultze; Brigitt Müller; Thomas Bruderer; Günter Dollenmaier; Julia M Riehm; Katia Boggian
Journal:  BMC Infect Dis       Date:  2012-10-04       Impact factor: 3.090

  9 in total
  2 in total

Review 1.  Melioidosis and the Heart: A Systematic Review.

Authors:  Ragani Velusamy; Stephen Muhi
Journal:  Trop Med Infect Dis       Date:  2020-07-23

2.  Challenges in Management of Disseminated Melioidosis with Endocarditis in a Patient with Chronic Kidney Disease.

Authors:  Adhiti Krishnamoorthy; Edwin Fernando; Prabhakar Dorairaj; Akshith Thimmaiah; D Suresh Kumar
Journal:  Indian J Nephrol       Date:  2020-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.